Loading
Deciphered the mutational signatures written in cancer genomes and turned them into clinical tests like HRDetect.
Serena Nik-Zainal led the whole-genome analysis of 560 breast cancers that catalogued mutational signatures and rearrangement patterns, and developed HRDetect, which identifies homologous recombination-deficient tumours beyond BRCA carriers and predicts PARP inhibitor sensitivity. Her group analysed the 100,000 Genomes Project cancers and builds signature-based tools for the NHS. She won the Francis Crick Medal in 2019.
Shares Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful, Whole-exome & whole-genome sequencing and the tags genomics, mutational-signatures.
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, Whole-exome & whole-genome sequencing, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag genomics.
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, Whole-exome & whole-genome sequencing and the tag genomics.
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC) and the tag uk.
Shares PARP, BRCA1 / BRCA2 (HRD) and the tag uk.
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC) and the tag uk.
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC) and the tag uk.
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, HR-positive / HER2-negative breast cancer.